Cell therapies save lives but can cost millions of dollars because of how slow and inefficient pharma R&D is. What if cell engineering was outsourced to synbio companies like Ginkgo that specialize in programming biology? This could be a game changer.
Ginkgo Has Hired A New Head Of Biopharma To Disrupt The Gene And Cell Therapies Market
